BioAdvance News

Galleon Pharmaceuticals Announces Publication of Proof-of-Concept Clinical Studies for GAL-021, Projected Use for the Emerging Perioperative Sleep Apnea Epidemic

By WebmasterSeptember 2, 2014November 1st, 2024No Comments

Galleon Pharmaceuticals Announces Publication of Proof-of-Concept Clinical Studies for GAL-021, Projected Use for the Emerging Perioperative Sleep Apnea Epidemic
Read more here

Previous PostNovira Therapeutics Announces Successful Completion of Phase 1a Clinical Study of NVR-1221 and Commencement of Phase 1b Clinical Studies
Next PostNovira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board

Galleon Pharmaceuticals Announces Publication of Proof-of-Concept Clinical Studies for GAL-021, Projected Use for the Emerging Perioperative Sleep Apnea Epidemic

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostNovira Therapeutics Announces Successful Completion of Phase 1a Clinical Study of NVR-1221 and Commencement of Phase 1b Clinical Studies

Next PostNovira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board